Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until March 6, 2026, to request to lead the case in the lawsuit titled Lupia v. Fermi Inc., et al., pending in the U.S. District Court for the Southern District of New York [3][12]. - The complaint includes securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Sections 11 and 15 of the Securities Act of 1933 [3]. Group 2: Company Background - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project, Project Matador, is designed to provide dedicated power for AI workloads [4]. Group 3: IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations state that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Group 4: Stock Performance - On December 12, 2025, Fermi's stock dropped by $5.16 per share, over 33%, following the termination of the Advance in Aid of Construction Agreement by the First Tenant [7][12].

Core Viewpoint - A class action lawsuit has been filed against CoreWeave, Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure, relying on partners like Core Scientific for development [4]. Allegations of Misconduct - The lawsuit claims that CoreWeave misrepresented its ability to meet customer demand and concealed significant construction delays at its data centers, which led to investor losses [5][13]. Stock Performance and Impact - CoreWeave's stock experienced notable declines: - On October 30, 2025, the stock dropped $8.87 (over 6%) after the merger with Core Scientific was terminated due to insufficient shareholder votes, falling from $139.93 to $131.06 [6]. - On November 11, 2025, the stock fell $17.22 (over 16%) after CoreWeave lowered its guidance for revenue and other metrics due to construction delays, dropping from $105.61 to $88.39 [7]. - On December 16, 2025, the stock decreased by $2.85 (over 3%) following reports of further delays in a major data center project, falling from $72.35 to $69.50 [8]. Legal Proceedings - Investors have until March 13, 2026, to request to lead the case in the U.S. District Court for the District of New Jersey, under the caption Masaitis v. CoreWeave, Inc., et al. [3][13].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3][10]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its accounts receivable collection practices, claiming to rely on "detailed reviews of historical collections," while actually using a 180-day cliff method for reserving uncollectable accounts [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses, constituting a violation of federal securities laws [4]. Group 3: Stock Performance Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and increased its professional liability reserves by $54 million, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 on November 13, 2025 [5][10].

Core Viewpoint - Eos Energy Enterprises, Inc. is under investigation for potential violations of federal securities laws, particularly concerning misleading statements about its revenue growth and manufacturing capabilities [1][3]. Group 1: Investigation Details - The investigation focuses on whether Eos made false and misleading statements to investors regarding its near-term revenue growth and the execution of its manufacturing efforts [3][10]. - Eos manufactures zinc-based long-duration battery energy storage systems aimed at supporting renewable energy and grid reliability [2]. Group 2: Financial Performance - Eos reported a significant net loss of approximately $970 million for fiscal year 2025, with revenue falling short of previously reaffirmed guidance [4]. - The company attributed its poor performance to high spending on scaling manufacturing operations, including inefficiencies and automation costs, as well as large non-cash financing and asset write-down charges [4]. - Eos also issued weaker-than-expected revenue guidance for 2026, citing slower production progress and increased execution risk [4]. Group 3: Stock Market Reaction - Following the announcement of its financial results, Eos's stock price dropped over 39% on February 26, 2026 [5][10].

Core Viewpoint - Kyndryl Holdings, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of materially misstated financial statements and inadequate internal controls during the class period from August 7, 2024, to February 9, 2026 [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Brander v. Kyndryl Holdings, Inc., and it allows purchasers of Kyndryl's publicly traded securities during the specified class period to seek appointment as lead plaintiff by April 13, 2026 [1][5]. - Allegations include that Kyndryl's financial statements were materially misstated and that the company lacked adequate internal controls, which led to an inability to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025 [3][4]. Group 2: Financial Impact and Company Response - On February 9, 2026, Kyndryl announced it would be unable to file its Quarterly Report on Form 10-Q on time, citing a review of its cash management practices and anticipated reporting of material weaknesses in internal controls [4]. - Following this announcement, Kyndryl's stock price fell by 55%, indicating a significant market reaction to the news [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit, highlighting its track record of recovering substantial amounts for investors in securities fraud cases [6].

Core Viewpoint - NuScale Power Corporation is facing a class action lawsuit due to alleged misleading statements regarding its commercialization partnership with ENTRA1 Energy LLC and significant financial losses reported in Q3 2025 [1] Company Overview - NuScale Power Corporation specializes in small modular nuclear reactors, specifically the NuScale Power Module (NPM) designed for energy generation [1] - The company entered a global commercialization partnership with ENTRA1 Energy LLC prior to the class action period, which was expected to advance its NPM technology from development to deployment [1] Allegations and Financial Impact - The lawsuit claims that NuScale and its executives made false statements about ENTRA1's capabilities, failing to disclose that ENTRA1 had no significant experience in building or operating nuclear power projects [1] - NuScale's general and administrative expenses surged over 3,000% to $519 million in Q3 2025, primarily due to a $495 million payment to ENTRA1 for the TVA agreement, leading to a net loss of $532 million, up from $46 million in the previous year [1] - Following the financial disclosures, NuScale's Class A shares dropped more than 12% over two days [1] Class Action Details - Investors who purchased NuScale Class A common stock between May 13, 2025, and November 6, 2025, can seek to be appointed as lead plaintiff in the class action lawsuit [1] - The lawsuit is titled Truedson v. NuScale Power Corporation, No. 26-cv-00328 (D. Or.) [1] Legal Representation - The law firm Robbins Geller Rudman & Dowd LLP is representing the plaintiffs and has a strong track record in prosecuting investor class actions, having recovered over $916 million for investors in 2025 alone [1]

Core Viewpoint - Paysafe Limited is facing a securities fraud class action lawsuit due to undisclosed risks related to its ecommerce business and financial performance, which led to significant losses for investors [3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Paysafe securities between March 4, 2025, and November 12, 2025, alleging that the company failed to disclose critical information regarding its financial health and client risks [3]. - Specific allegations include significant exposure to a high-risk client, understated credit loss reserves, and issues with higher risk Merchant Category Codes, all of which negatively impacted revenue growth and financial guidance for fiscal year 2025 [3]. Group 2: Financial Impact - On November 13, 2025, Paysafe reported third-quarter financial results that missed revenue and EPS estimates, citing a last-minute client shutdown that resulted in a multi-million dollar write-down [4]. - The company's credit loss expense for the three months ended September 30, 2025, was reported at $13,220, primarily due to expected chargebacks related to a specific merchant [4]. - Following the financial report, Paysafe's share price dropped by $2.80, or approximately 27.6%, from $10.16 on November 12, 2025, to $7.36 on November 13, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Lakeland Industries, Inc. for securities fraud, alleging that the company made false and misleading statements regarding its business operations and financial results during the Class Period from December 1, 2023, to December 9, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that Lakeland was facing significant issues with its Pacific Helmets and Jolly businesses, including shipping delays, production issues, and a slower rollout of new products [1]. - Defendants allegedly overstated the positive impact of these businesses on Lakeland's financial results and the overall strength of their operations [1]. - The lawsuit indicates that Lakeland's financial results were deteriorating due to tariff-related headwinds, certification delays, and material flow issues in its acquired businesses [1]. Group 2: Financial Guidance and Public Statements - The defendants are accused of overstating the effectiveness of their tariff mitigation measures and their "small, strategic, and quick" M&A strategy [1]. - As a result of the aforementioned issues, the financial guidance provided by the defendants was deemed unreliable [1]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading throughout the Class Period [1].

BRBR Deadline: BRBR Investors Have Opportunity to Lead BellRing Brands, Inc. Securities Fraud Lawsuit [Accessibility Statement] Skip NavigationNEW YORK, Feb. 27, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bellring Brands, Inc. (NYSE: BRBR) between November 19, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), of the important March 23, 2026 lead plaintiff deadline.So what: If you purchased BellRing securities during the C ...

Core Viewpoint - Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is facing a securities fraud lawsuit, with a lead plaintiff deadline set for March 16, 2026, for investors who purchased common stock between April 1, 2024, and December 16, 2025 [1] Group 1: Lawsuit Details - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is in development for treating social anxiety disorder (SAD) [1] - Defendants reportedly made positive assertions about fasedienol's trial success based on prior results from the PALISADE-2 clinical trial, while concealing adverse facts about the Phase 3 PALISADE-3 trial [1] - Investors are claimed to have suffered damages when the true details about the trial were revealed [1] Group 2: Legal Representation - The Rosen Law Firm is encouraging investors to join the class action and emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [1] - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [1] - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]